MSE MBA - Ensysce Biosciences Chief Officer
| ENSC Stock | USD 0.59 0.07 10.61% |
Insider
MSE MBA is Chief Officer of Ensysce Biosciences
| Age | 52 |
| Address | 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037 |
| Phone | 858 263 4196 |
| Web | https://www.ensysce.com |
Ensysce Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.3194) % which means that it has lost $1.3194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2789) %, meaning that it created substantial loss on money invested by shareholders. Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 34.52, whereas Return On Tangible Assets are forecasted to decline to (4.11). At present, Ensysce Biosciences' Other Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
Management Performance
| Return On Equity | -4.28 | ||||
| Return On Asset | -1.32 |
Ensysce Biosciences Leadership Team
Elected by the shareholders, the Ensysce Biosciences' board of directors comprises two types of representatives: Ensysce Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ensysce. The board's role is to monitor Ensysce Biosciences' management team and ensure that shareholders' interests are well served. Ensysce Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ensysce Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David CPA, Secretary CFO | ||
| MSE MBA, Chief Officer | ||
| Geoffrey Birkett, Chief Officer | ||
| Lynn Kirkpatrick, CEO President | ||
| Jeffrey Millard, Chief Officer | ||
| Linda Pestano, Chief Officer | ||
| William Schmidt, Chairman Officer |
Ensysce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ensysce Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.28 | ||||
| Return On Asset | -1.32 | ||||
| Operating Margin | (10.76) % | ||||
| Current Valuation | 9.07 M | ||||
| Shares Outstanding | 19.57 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 22.26 % | ||||
| Number Of Shares Shorted | 6.35 M | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 8.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.